

Neurotech secures \$3.15 million R&D tax incentive loan

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), advises that it has entered into a secured loan agreement and specific security agreement with Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust (**Rockford**) for a secured loan of \$3.15 million (**Loan Agreements**).

The loan will provide Neurotech with non-dilutive funding secured against the Company's anticipated refundable research and development tax incentive offsets for FY2026 and FY2027.

The key terms of the Loan Agreements are set out in Annexure A. The Loan Agreements are otherwise on terms considered customary for agreements of their type. The loan proceeds will be used to support the Company's Phase III Clinical Studies in ASD, ongoing research and development activities and general working capital purposes.

Authority

This announcement was authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

ANNEXURE A – MATERIAL TERMS OF LOAN AGREEMENTS

Term	Details
Lender	Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust
Loan amount	\$3,150,000 (excluding capitalised establishment fee)
Drawdown	Single drawdown, subject to satisfaction or waiver of conditions precedent
Establishment fee	1.0% of the loan amount, being \$31,500, capitalised into the loan balance at drawdown
Interest rate	16.0% per annum, calculated daily on the outstanding loan balance (including capitalised interest)
Default interest rate	20.0% per annum
Minimum term	120 days from the date of the agreement
Maturity date	31 December 2027, which can be extended by the Company by 30 days by paying the lender a fee equal to the greater of \$3,000 or 1% of all outstanding amounts owing to the lender as at the relevant time
Security	First-ranking security over the Company's anticipated FY2026 and FY2027 refundable research and development tax incentive offsets and the proceeds of each
Repayment	The facility is expected to be repaid in two tranches from the Company's FY2026 and FY2027 refundable research and development tax incentive offsets

For personal use only